(RTTNews) - Mind Medicine (MindMed) Inc. (MNMD) said the FDA has placed a clinical hold on its IND submission intended to support the initiation of a phase 2b trial of lysergic acid diethylamide for the treatment of generalized anxiety disorder.
Robert Barrow, CEO of MindMed, said: "We remain highly confident in the therapeutic potential of lysergic acid diethylamide to usher in a new treatment paradigm for these disorders and we look forward to working closely with FDA to satisfy all outstanding concerns as rapidly as possible."
MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies.
Shares of MindMed were down 7% in pre-market trade on Tuesday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
